Clinical Trial Update: Correction Study of R744 in Renal Anemia Patients on Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3 correction study of R744 in renal anemia patients on hemodialysis has completed, sponsored by Chugai Pharmaceutical.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• R744

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Hemodialysis Patients | Phase 3 | Status: COMPLETED